CIK细胞治疗晚期肝癌患者免疫功能变化及安全性评价  

Evaluation of Immune Function Changing and Safety of Autologous Cytokine-induced Killer Cell for Advanced Hepatocellular Carcinoma

作　　者：陈敬华[1,2] 郑欣 申维玺[1,2] 许瑞莲[1,2] 夏俊贤[1,2] 田忠凯[1,2] 

机构地区：[1]暨南大学第二临床医学院 [2]深圳市人民医院肿瘤内科,广东深圳518020 [3]深圳市人民医院药学部,广东深圳518020

出　　处：《肿瘤基础与临床》2013年第4期334-337,共4页journal of basic and clinical oncology

基　　金：深圳市科技计划项目(编号:201203123)

摘　　要：目的评价细胞因子诱导杀伤细胞(CIK)治疗晚期肝癌患者的细胞免疫功能变化及安全性。方法检测30例健康志愿者和98例晚期肝癌患者经导管肝动脉化疗栓塞(TACE)术前、术后第7天、CIK回输后第7天的外周血T细胞亚群变化,并观察CIK细胞治疗的毒副反应。结果肝癌患者外周血CD3+、CD3+CD4+细胞比例、CD4+/CD8+比值明显低于健康志愿者。CIK治疗后外周血CD3+、CD3+CD4+细胞的比例显著增多,CD4+/CD8+比值升高。CIK细胞回输后,17例患者出现发热,持续时间2～4 h,大部分自行消退,无其他毒副反应。结论 TACE术后序贯应用CIK细胞过继性免疫治疗,可以提高晚期肝癌患者的细胞免疫功能,安全性良好,有助于降低晚期肝癌患者TACE术后的复发和转移机会。Objective To evaluate the cellular immune function changes and safety of advanced hepatocellular carcinoma treated by autologous cytokine-induced killer cell. Methods Thirty healthy volunteers and 98 patients with advanced hepatocellular carcinoma were included in the study. Peripheral blood samples collected from the 30 healthy volunteers and the 98 patients at different time points were analyzed by flow cytometry. The lymphocyte subsets of the total lymphocytes were determined, and the toxicities were observed. Results The percentages of CD3^＋ , CD3 ^＋ CD4 ^＋ , and CD4 ^＋/CD8 ^＋ ratios from the patients with hepatocellular carcinoma were significantly lower than those from healthy volunteers. The percentages of CD3 ^＋ , CD3^ ＋ CD4 ^＋ and CD4 ^＋/CD8 ^＋ ratios were increased significantly after autologous CIK cell transfusion. Seventeen patients occurred fever after CIK cell transfusion lasting for 2-4 hours. Most febrile patients recovered without any treatment. There were no other toxicities. Conclusion Sequential application of CIK cell adoptive immnnotherapy after TACE increases the immune function of patients with advanced bepatocellular carcinoma, and may be helpful to reduce the chance of recurrence and metastasis in patients with advanced hepatocellular carcinoma.

关 键 词：细胞因子诱导杀伤细胞 肝癌 有效性 安全性 

分 类 号：R735.7[医药卫生—肿瘤] R730.54[医药卫生—临床医学]